Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

被引:420
作者
Coppell, Jason A. [1 ]
Richardson, Paul G. [2 ]
Soiffer, Robert [2 ]
Martin, Paul L. [3 ]
Kernan, Nancy A. [4 ]
Chen, Allen [5 ]
Guinan, Eva [2 ]
Vogelsang, Georgia [5 ]
Krishnan, Amrita [6 ]
Giralt, Sergio [7 ]
Revta, Carolyn [2 ]
Carreau, Nicole A. [2 ]
Iacobelli, Massimo [8 ]
Carreras, Enric [9 ]
Ruutu, Tapani [10 ]
Barbui, Tiziano [11 ]
Antin, Joseph H. [2 ]
Niederwieser, Dietger [12 ]
机构
[1] Royal Devon & Exeter Hosp, Haematol Ctr, Dept Haematol, Exeter EX2 5DW, Devon, England
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] City Hope Canc Ctr, Duarte, CA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[8] Gentium SpA, Villa Guardia, Italy
[9] Hosp Clin Barcelona, Barcelona, Spain
[10] Univ Helsinki, Cent Hosp, Helsinki, Finland
[11] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[12] Univ Leipzig, Leipzig, Germany
关键词
Veno-occlusive disease; Stem cell transplantation; Incidence; Outcome; Severity; Multiorgan failure; BONE-MARROW-TRANSPLANTATION; ACUTE-RENAL-FAILURE; SINUSOIDAL OBSTRUCTION SYNDROME; ORGAN DYSFUNCTION SYNDROME; DAILY INTRAVENOUS BUSULFAN; HIGH-DOSE CHEMOTHERAPY; TISSUE-PLASMINOGEN ACTIVATOR; CHRONIC MYELOID-LEUKEMIA; VENO-OCCLUSIVE DISEASE; TOTAL-BODY IRRADIATION;
D O I
10.1016/j.bbmt.2009.08.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of patients following stem cell transplantation (SCT), with incidence varying widely between studies depending on the type of transplant, conditioning regimen, and criteria used to make the diagnosis. Severe VOD is characterized by high mortality and progression to multiorgan failure (MOF); however, there is no consensus on how to evaluate severity. This review and analysis of published reports attempts to clarify these issues by calculating the overall mean incidence of VOD and mortality from severe VOD, examining the effect of changes in SCT practice on the incidence of VOD over time, and discussing the methods used to evaluate severity. Across 135 studies performed between 1979 and October 2007, the overall mean incidence of VOD was 13.7% (95% confidence interval [Cl] = 13.3%-14.1%). The mean incidence of VOD was significantly lower between 1979-1994 than between 1994-2007 (11.5% [95% Cl, 10.9%-12.1%] vs 14.6% [95% Cl, 14.0%-15.2%]; P<.05). The mortality rate from severe VOD was 84.3% (95% Cl, 79.6%-88.9%); most of these patients had MOF, which also was the most frequent cause of death. Thus, VOD is less common than early reports suggested, but the current incidence appears to be relatively stable despite recent advances in SCT, including the advent of reduced-intensity conditioning. The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome. Biol Blood Marrow Transplant 16: 157-168 (2010) (C) 2010 American Society for Blood and Marrow Transplantation
引用
收藏
页码:157 / 168
页数:12
相关论文
共 143 条
  • [1] OUTCOME OF RECIPIENTS OF BONE-MARROW TRANSPLANTS WHO REQUIRE INTENSIVE-CARE UNIT SUPPORT
    AFESSA, B
    TEFFERI, A
    HOAGLAND, HC
    LETENDRE, L
    PETERS, SG
    [J]. MAYO CLINIC PROCEEDINGS, 1992, 67 (02) : 117 - 122
  • [2] Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study
    Andersson, BS
    Kashyap, A
    Gian, V
    Wingard, JR
    Fernandez, H
    Cagnoni, PJ
    Jones, RB
    Tarantolo, S
    Hu, WW
    Blume, KG
    Forman, SJ
    Champlin, RE
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (03) : 145 - 154
  • [3] Armitage P, 1987, STAT METHODS MED RES, V2, P117
  • [4] ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P385
  • [5] ATTAL M, 1992, BLOOD, V79, P2834
  • [6] Haploidentical stem cell transplantation for acute leukemia
    Aversa, F
    Terenzi, A
    Felicini, R
    Carotti, A
    Falcinelli, F
    Tabilio, A
    Velardi, A
    Martelli, MF
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 1) : 165 - 168
  • [7] HEPATIC VENOOCCLUSIVE DISEASE IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION OF SOLID TUMORS AND LYMPHOMAS
    AYASH, LJ
    HUNT, M
    ANTMAN, K
    NADLER, L
    WHEELER, C
    TAKVORIAN, T
    ELIAS, A
    ANTIN, JH
    GREENOUGH, T
    EDER, JP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) : 1699 - 1706
  • [8] Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment
    Bajwa, RPS
    Cant, AJ
    Abinun, M
    Flood, T
    Hodges, S
    Hale, JP
    Skinner, R
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 (07) : 591 - 597
  • [9] GI complications in pediatric patients post-BMT
    Barker, CC
    Anderson, RA
    Sauve, RS
    Butzner, JD
    [J]. BONE MARROW TRANSPLANTATION, 2005, 36 (01) : 51 - 58
  • [10] Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients
    Barker, CC
    Butzner, JD
    Anderson, RA
    Brant, R
    Sauve, RS
    [J]. BONE MARROW TRANSPLANTATION, 2003, 32 (01) : 79 - 87